Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease
Open Access
- 6 April 2020
- journal article
- Published by Elsevier BV in eNeurologicalSci
- Vol. 19, 100239
- https://doi.org/10.1016/j.ensci.2020.100239
Abstract
No abstract availableKeywords
Funding Information
- Grants-in-Aid for Advanced Research and Development Programs for Medical Innovation, Scientific Research (19H03708, 19K07635, 17K09774, 15K19475)
- Takeda Science Foundation, Naito Foundation, Novartis Foundation, Uehara Memorial Foundation, and GSK Japan Research Grant 2018
This publication has 31 references indexed in Scilit:
- The Functional DRD3 Ser9Gly Polymorphism (rs6280) Is Pleiotropic, Affecting Reward as Well as MovementPLOS ONE, 2013
- Pentanucleotide repeat-primed PCR for genetic diagnosis of spinocerebellar ataxia type 31Journal of Human Genetics, 2012
- Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese populationBMC Neurology, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Molecular mechanisms of L-DOPA-induced dyskinesiaNature Reviews Neuroscience, 2008
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 yearsMovement Disorders, 2008
- Genetics of Parkinson disease: paradigm shifts and future prospectsNature Reviews Genetics, 2006
- Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotypeNature Neuroscience, 2005
- Investigation of the functional effect of monoamine oxidase polymorphisms in human brainHuman Genetics, 2001
- Studies of the potential role of the dopamine D1 receptor gene in addictive behaviorsMolecular Psychiatry, 1997